Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

NCT00969293 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema
Central Retinal Vein Occlusion

Interventions

DRUG: FOV2302 (Ecallantide)

Sponsor

Fovea Pharmaceuticals SA